Related Experiment Videos
Gastrointestinal non-Hodgkin's lymphoma
A R Makepeace1, D C Fermont, M H Bennett
1Meyerstein Institute of Radiotherapy and Oncology, Middlesex Hospital, London.
Clinical Radiology
|November 1, 1987
Summary
This study reviewed 72 gastrointestinal non-Hodgkin's lymphoma cases from 1952-1980. Most patients had Grade 2 lymphoma, with low 5-year survival rates indicating a need for improved treatment strategies.
Area of Science:
- Oncology
- Gastroenterology
- Hematology
Background:
- Gastrointestinal non-Hodgkin's lymphoma (GI-NHL) is a rare malignancy.
- Treatment strategies and outcomes for GI-NHL have evolved over time.
- Understanding historical treatment patterns is crucial for evaluating current therapeutic approaches.
Purpose of the Study:
- To review treatment outcomes for gastrointestinal non-Hodgkin's lymphoma patients treated between 1952 and 1980.
- To analyze the distribution of lymphoma involvement in the gastrointestinal tract.
- To assess the impact of different treatment modalities on survival and relapse rates.
Main Methods:
- Retrospective review of 72 patients diagnosed with gastrointestinal non-Hodgkin's lymphoma.
- Analysis of treatment modalities including surgical resection, radiotherapy, and chemotherapy.
- Histological review using British National Lymphoma Investigation criteria.
- Evaluation of overall and relapse-free survival rates at 5 years.
Main Results:
- The small intestine was involved in 49% of cases, and the stomach in 29%.
- Overall 5-year survival was 36%, with a 5-year relapse-free survival of 22%.
- Fifty-seven percent of patients relapsed, and 80% of those relapsed patients died from lymphoma.
- 94% of cases were reclassified as Grade 2 non-Hodgkin's lymphoma.
Conclusions:
- Gastrointestinal non-Hodgkin's lymphoma historically had poor survival outcomes.
- Treatment approaches varied based on disease extent and resectability.
- The high relapse rate underscores the need for more effective therapeutic strategies for GI-NHL.